Clinical Trials in Vadodara, Gujarat
20 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled74 locationsNCT06951711
Recruiting
Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Sickle Cell Disease
Novo Nordisk A/S408 enrolled172 locationsNCT06612268
Recruiting
Phase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
Bristol-Myers Squibb450 enrolled170 locationsNCT06929273
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
MASH With FibrosisNASH With Fibrosis
Akero Therapeutics, Inc1,650 enrolled349 locationsNCT06215716
Recruiting
Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular RiskAcute Myocardial Infarction (AMI)
Novo Nordisk A/S10,000 enrolled970 locationsNCT06118281
Recruiting
Phase 3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled240 locationsNCT06200207
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 2
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Novo Nordisk A/S200 enrolled92 locationsNCT06979375
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Novo Nordisk A/S200 enrolled109 locationsNCT06979362
Recruiting
Phase 1
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled19 locationsNCT06755450
Recruiting
Phase 4
A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
Hypovolemic Shock
Pharmazz, Inc.400 enrolled17 locationsNCT05956418
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Triple-Negative Breast Cancer
Jina Pharmaceuticals Inc.657 enrolled4 locationsNCT03671044
Recruiting
Not Applicable
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
Vulvovaginal candidiasis
The Archer-Daniels-Midland Company126 enrolled6 locationsNCT06480604
Recruiting
Phase 1
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Solid Tumor, Adult
Aurigene Discovery Technologies Limited40 enrolled9 locationsNCT05605119